B04 | OVERALL SURVIVAL AND DURATION OF TRANSFUSION INDEPENDENCE FOR FIRST-LINE ERYTHROPOIESIS STIMULATING AGENT-NAIVE PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH LUSPATERCEPT VS. EPOETIN ALFA: COMMANDS TRIAL

BACKGROUND: The phase 3 COMMANDS study (NCT03682536) showed that LUSPA improved red blood cell (RBC)-TI ≥12 wks with a concurrent hemoglobin increase of ≥1.5 g/dL in Wks 1 to 24 compared with EA and had durable clinical benefit in pts with ESA-naive TD LR-MDS. Here, we report updated OS and duratio...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	V. Santini, M. Della Porta, A. Zeidan, R.S. Komrokji, V. Pozharskaya, S. Rose, K. Keeperman, Y. Lai, S. Kalsekar, B. Aggarwal, D. Miteva, D. Valcárcel, P. Fenaux, J. Shortt, U. Platzbecker, G. Garcia-Manero
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Ferrata Storti Foundation 2025-09-01
Rangatū:	Haematologica
Urunga tuihono:	https://haematologica.org/article/view/12856
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!